Chimeric antigen receptor (CAR) T cell therapy has the potential to fundamentally shift the treatment of autoimmune disease. During his presentation at EULAR 2024, Georg Schett, MD, provided an overview of this treatment process and described the promising findings of the latest research.
As uncertainty persists around federal policies regarding copay accumulator programs, a growing number of states are stepping in. A total of 21 states have banned the programs and others are increasing transparency requirements
An ACR-led resolution that calls for Medicaid payment parity for pediatric specialists will become AMA policy.
A school science project demonstrates that flipbooks can be a useful educational tool for patients and their families to learn about rheumatic conditions and their treatment.
Mannion et al. set out to describe the adult rheumatology workforce in the U.S. by measuring the number of rheumatologists and advanced practice providers entering and exiting the field and studying their demographics.
It’s an election year, and ACR staff are excited about the possibility of moving key initiatives, such as Medicare reimbursement, across the finish line. But they need members’ help to do so.
August marks an in-district work period for federal legislators. This offers a great opportunity for ACR/ARP members to engage with their lawmakers to complement the ACR’s formal lobbying efforts.
SAN DIEGO—As part of a Nov. 14 session on lupus nephritis at ACR Convergence 2023, Simone Appenzeller, MD, PhD, shared perspectives on the importance of biopsy to inform its diagnosis, prognosis and treatment, with an emphasis on childhood disease. Prompt diagnosis and treatment of lupus nephritis is perhaps even more important for children than for…
Kidney involvement is a major cause of morbidity and mortality in systemic lupus erythematosus (SLE). Collectively termed lupus nephritis, SLE with kidney involvement comes in many subtypes. The current classification by the International Society of Nephrology/Renal Pathology Society (ISN/RPS), however, does not include lupus podocytopathy, which, through various clinical and epidemiologic studies, has recently been…
In 2022, an international group of researchers reported the seminal finding that a gain-of-function variant of a single-stranded ribonucleic acid (RNA) sensor, known as toll-like receptor 7 (TLR7), can cause human systemic lupus erythematosus (SLE).1 The paper in Nature showed that a newly described variant of TLR7, identified in a child with severe lupus, was…